Truist keeps USD 51 target for Boston Scientific stock

Published on 10/16/2026 at 15:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 7.50 percent to USD 5.44 billion. Boston Scientific stock costs EUR 39.57 on October 16, 2026 at 3:14 p.m. CEST.

Analyst target before results

Truist Financial maintained a USD 51.00 target on October 14, 2026.
Second-quarter revenue rose 7.50 percent to USD 5.44 billion.
Boston Scientific stock costs EUR 39.57 at Lang & Schwarz on October 16, 2026 at 3:14 p.m. CEST.
Boston Scientific is scheduled to report third-quarter results on October 28, 2026.

Flatlay auf Marmor mit Aktienzertifikat, ISIN-Karte US1011371077, Bürogebäude-Miniatur und Schlüsseln — Boston Properties US1011371077 symbolisiert durch Aktienzertifikat, ISIN-Karte und Bürogebäude-Modell auf weißem Marmor, Illustration mit AI erstellt.

Truist Financial maintained a USD 51.00 price target for Boston Scientific on October 14, 2026, putting the target 15.54 percent above the NYSE price of USD 44.14. Boston Scientific stock was trading at EUR 39.57 at Lang & Schwarz on October 16, 2026, at 3:14 p.m. CEST.

Truist target stays at USD 51.00

According to Markets Insider, Truist analyst Richard Newitter kept a Buy rating and a USD 51.00 target in a report released on October 14, 2026. The target comparison uses the USD 44.14 closing price on the NYSE from October 15, 2026 and shows a 15.54 percent gap.

Revenue reached USD 5.44 billion

Boston Scientific generated USD 5.44 billion in revenue during the second quarter of 2026, up 7.50 percent from the year-earlier period. The company reported USD 907.0 million in net income attributable to common shareholders and diluted earnings per share of USD 0.61 for the same quarter. The official Boston Scientific newsroom dated the quarterly release July 29, 2026.

Stock stays near its yearly low

The USD 44.14 NYSE price on October 15, 2026 stood within the USD 41.39 to USD 105.65 52-week range. That leaves the stock 4.00 percent above its 52-week low and 58.20 percent below its 52-week high. Boston Scientific's market capitalization was USD 64.0 billion, while its price-to-earnings ratio was 17.94.

Results date is October 28

MarketBeat lists October 28, 2026 as the expected date for Boston Scientific's third-quarter results, before the market opens. Its consensus calls for revenue of USD 5.10 billion and earnings per share of USD 0.7460.

Comparison with peers

Boston Scientific (NYSE, USD): P/E 17.94, market capitalization USD 64.0 billion
Medtronic (NYSE, USD): up 1.29 percent, P/E 23.51, market capitalization USD 122.1 billion
Abbott Laboratories (NYSE, USD): up 2.30 percent, P/E 33.66, market capitalization USD 181.2 billion

Price remains the market frame

The target, quarterly revenue and upcoming results date give investors three separate reference points for Boston Scientific. The stock's position near its 52-week low contrasts with the USD 51.00 target, while the next report will test whether the USD 5.44 billion quarterly revenue base can support the company's outlook.

The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.